Search results | bristol-myers squibb

Bristol-Myers Squibb joins hands with MMRF to be pharma partners

Bristol-Myers Squibb, a big pharma company & Multiple Myeloma Research Foundation (MMRF) have signed a deal to be pharma partners. In the light of this pharma partners agreement, Bristol-Myers Sqibb will join MMRF’s  pre-competitive consortium to discover and accelerate new approaches to treating multiple myeloma through the organization’s Personalized Medicine Initiative. For further deal information visit Current Agreements (subscrip…

New pharma deals signed between Bristol-Myers Squibb & Synergy Pharmaceuticals

Bristol-Myers Squibb, a top big pharma company has inked an Asset Purchase pharma deals Agreement with Synergy Pharmaceuticals and has acquired the assets related to FV-100. FV-100 is an orally available nucleoside analogue, currently being developed for the treatment of shingles, a severe, painful skin rash caused by reactivation of the varicella zoster virus — the virus that causes chickenpox. For further deal information visit Current A…

Breakthrough pharma deals: Summit inks Seglin deal with Bristol-Myers Squibb

has enteredwith Bristol-Myers Squibb, a top pharma company has signed  a technology license agreement  with Summit which can be termed as one of the breakthrough pharma deals. Bristol-Myers Squibb will use Summit’s proprietary Seglin technology as a part of this pharma deals signing to identify and develop drug candidates for up to ten targets across multiple therapeutic areas. Under the terms of this pharma deals agreement, Bristol-Myers Squibb

Bristol-Myers Squibb eyes big deal, biotech rumour mill

…pharma company, decides it needs a big acquisition to get out of the doldrums, it may find itself competing with Bristol-Myers Squibb .  The Wall Street Journal reports that Bristol-Myers has been kicking tires around the industry, most recently at Biogen Idec . The Journal‘s sources say BMS looked closely at a Biogen buyout in recent months. Before that, it hired financial advisers to analyze a possible deal for Shire . Biogen has a $39 bi…

Dealmakers weekly review – July 3 2012 – Amylin, Bristol-Myers Squibb, AstraZeneca, Biogen Idec, Celgene, Inhibrx

…he weeks dealmaking The review The major deal story from last week was the $5.3 billion acquisition of Amylin by Bristol-Myers Squibb. The subsequent $3.4 billion collaboration and marketing pact between Bristol-Myers Squibb and AstraZeneca for Amylin’s diabetes portfolio, was key to the BMS-Amylin transaction. On the M&A front in addition to the above, the other major deal of the week was the $1.2 billion acquisition of Robust Sun Hold…

Bristol-Myers Squibb in Mutli Year strategic pharma alliances deal with Prosetta Antiviral

Prosetta Antiviral announced the execution of a strategic pharma alliances agreement with Bristol-Myers Squibb. a big pharma company to further discover and develop select drug candidates representing new, novel classes of antiviral drugs. The pharma alliances collaboration will include a research program focused on the discovery and advancement of compounds shown to block viral capsid assembly using Prosetta’s proprietary drug discovery platfor…

Bristol-Myers Squibb Foundation announces grants focussed on prevention, diagnosis and care of Hepatitis B and Hepatitis C in Asia

The Bristol-Myers Squibb Foundation has awarded three new grants to improve prevention, diagnosis and care of hepatitis B (HBV) and hepatitis C (HCV) in China and India as part of its Delivering Hope: Awareness, Prevention and Care umbrella program which is committed to reducing hepatitis-related health disparities in Asia.  The grant recipients, which range in scope from national and regional government health, charitable non-profit and advocac…

Amylin shares rocket up on report of $3.5 billion buyout offer by Bristol-Myers Squibb

…in a telephone interview. “There are much bigger commercial organizations and companies that probably more than Bristol need to augment their franchises.” Amylin jumped 54 percent to $23.77 at the close in New York for the biggest single-day increase since August 1999. The shares have more than doubled in the last 12 months. Bristol- Myers, based in New York, was unchanged at $33.67, and has gained 25 percent in the last 12 months. Jennifer Maue…

Partnering Agreements with Bristol-Myers Squibb 2005-2012

This report provides all the information you require to better understand Bristol-Myers Squibb and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identif…

Bristol-Myers Squibb: Partnering activity 2005-2013

Bristol-Myers Squibb announced over 160 partnering / licensing deals since 2005, with over 30 deals in 2012 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in oncology, cardiovascular, infectives, metabolic and psychiatric diseases. Abstracted from: Partnering Deals and Alliances with Bristol-Myers Squibb The number of partnering, collaborative R&D and licensing deals announced remained steadily year on year w…

ca300x150gif
biotechnology-2014header300x150pxjpg
ft-us-healthcare300x150gif
RSS Feed Linked In Twitter

Latest Tweets

cp300x1502gif
cbpf14banner300x150jpg
ft-us-healthcare300x150gif